|本期目录/Table of Contents|

[1]武志黔 郝改梅 薛晓兴 何洁等.葛根芩连汤对2型糖尿病模型大鼠作用 的研究[J].环球中医药,2014,7(03):161-0.
　WU Zhi qian,HAO Gai mei,XUE Xiao xing,et al.Research on the effect of Gegenqinlian Decoction on type 2 diabetic model[J].,2014,7(03):161-0.
点击复制

葛根芩连汤对2型糖尿病模型大鼠作用 的研究()
     
分享到：

《环球中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
第7卷
期数:
2014年03期
页码:
161-0
栏目:
论著
出版日期:
2014-03-06

文章信息/Info

Title:
Research on the effect of Gegenqinlian Decoction on type 2 diabetic model
作者:
武志黔 郝改梅 薛晓兴 何洁等
Author(s):
WU Zhiqian;  HAO Gaimei;  XUE Xiaoxing;  et al.
College of Basic Medicine, Beijing University of Chinese Medicine, Beijing 100102, China
关键词:
葛根芩连汤; 西格列汀; 2型糖尿病; 胰岛素耐量; 葡萄糖耐量
Keywords:
Gegenqinlian Decoction; Sitagliptin; Type 2 diabetes; Insulin tolerance; Glucose tolerance
分类号:
R2554
DOI:
-
文献标志码:
A
摘要:
目的探索葛根芩连汤单药及联合西格列汀对2型糖尿病模型大鼠血糖值、胰岛素耐量、葡萄糖耐量的作用，从而初步揭示葛根芩连汤治疗2型糖尿病的生物学机制。方法采用高脂饲料喂养合并链脲佐菌素（streptozotocin,STZ）诱导建立2型糖尿病模型大鼠58只，予以无菌水（正常组和模型组）、葛根芩连汤（中药组）、西格列汀（西药组）、葛根芩连汤联合西格列汀（中加西组）给药6周的治疗方案，动态监测各组模型动物体重、空腹血糖（fasting blood glucose, FBG），以及给药前、给药后3周、给药后6周的胰岛素耐量试验和葡萄糖耐量试验。结果给药6周后，与模型组相比，中药组FBG降低（P＜005），葡萄糖耐量改善（P＜005）；西药组体重降低改善（P＜005），FBG降低（P＜005），胰岛素耐量、葡萄糖耐量改善（P＜005）；中加西组体重降低改善（P＜005），FBG降低明显（P＜001），胰岛素耐量、葡萄糖耐量均改善明显（P＜001）。给药各组疗效顺序如下：中加西组＞西药组＞中药组。结论葛根芩连汤与西格列汀单独使用时，西药组疗效优于中药组，联合使用时其疗效明显优于两药单独使用，表明葛根芩连汤对西格列汀的疗效有一定的辅助作用。
Abstract:
ObjectiveTo explore the effect of Gegenqinlian Decoction, sitagliptin monotherapy or combination therapy on the blood glucose, insulin tolerance, glucose tolerance of rat model of type 2 diabetes, and initially reveal the biological mechanisms of treating type 2 diabetes Gegenqinlian Decoction. Methods58 high fat diet combined STZinduced type 2 diabetic model, be given the treatment with water (normal group and model group), Gegenqinlian Decoction (Chinese medicine group), sitagliptin (western medicine group), sitagliptin Gegenqinlian Decoction joint (combination group), dynamic monitoring model animal body weight, fasting blood glucose (FBG), and the insulin tolerance tests and glucose tolerance tests of predose, after administration of 3 weeks and 6 weeks in each group. ResultsAfter 6 weeks administration, compared with the model group, Chinese medicine group FBG was lower (P＜005), and has improvement in glucose tolerance (P＜005); western medicine group improved weight loss (P＜005), FBG was lower (P＜005), and has both insulin resistance and impaired glucose tolerance improvement (P＜005); combination group improved weight loss (P＜005), FBG was significantly lower (P＜001), insulin resistance and impaired glucose tolerance were improved significantly (P＜001). The order of efficacy of each group were as follows: combination group＞western medicine group＞Chinese medicine group. ConclusionFor the monotherapy of Gegenqinlian Decoction or sitagliptin, western medicine group was more effective than the traditional Chinese medicine group, while its efficacy when used in combination was significantly better than the two drugs used alone, indicating Gegenqinlian may play a supplementary role to the efficacy of sitagliptin.

参考文献/References:

[1]黄泰康，施诚．中药方剂现代研究大典［M］．北京：科学技术出版社，1996．
[2］邢颖，郑策，甄健存．二肽基肽酶DPP4抑制剂西格列汀治疗2型糖尿病的安全性国内外文献分析［J］．中国医院药学杂志，2012，32(6)：480481．
[3］吴晏，韩静，黄黎明，等．高脂喂养合并小剂量链脲佐菌素建立2型糖尿病大鼠模型［J］．中国实验动物学报，2012，20(2)：1115．
[4］张金莲，张忠伟，王颖怡，等．葛根芩连汤对2型糖尿病大鼠肾脏的量效关系研究［J］．江西中医学院学报，2012，24(4)：6164.
[5］潘秋，赵慧辉，陈建新，等．2型糖尿病实验大鼠表征及其证候特征研究［J］．中华中医药杂志，2011，26(4)：683685．
[6］周艳，谭海荣，潘竞锵，等．葛根芩连汤对2型糖尿病大鼠的降血糖抗氧化作用［J］．中国新医学，2003，2(6)：1718．
[7］潘竞锵，韩超，刘惠纯，等．葛根芩连汤降血糖作用的实验研究［J］．中国新药杂志，2000，9(3)：167170．
[8］李颖萌，范雪梅，王义明，等．葛根芩连汤对2型糖尿病大鼠的治疗作用及其机制探讨［J］．药学学报，2013，48(9)：14151421．
[9］赵林华，姬航宇，冀博文，等．葛根芩连汤治疗糖尿病理论探讨［J］．中华中医药杂志，2012，27(2)：280283．
[10］沈春莲，张凌云，陆少锋．西格列汀治疗2型糖尿病的疗效［J］．现代医院，2013，13(6)：2829．
[11］王兴民，季海锋，李立伟，等．西格列汀治疗2型糖尿病近期降糖效果的临床观察［J］．海峡药学，2012，24(1)：9394．
[12］胡洁，安富荣．西格列汀治疗2型糖尿病的临床研究进展［J］．医药导报，2013，32(6)：760764．
[13］Srinivasan K, Viswanad B, Asrat L, et al Combination of highfat dietfed and lowdose streptozotocintreated rat: a model for type 2 diabetes and pharmacological screening ［J］.Pharmacol Res, 2005, 52(4): 313320.
[14］Kahn SE, Hull R, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes ［J］ Nature, 2006, 444(7121): 840846
[15］刘志霞双益降糖方对2型糖尿病大鼠的作用及其机制初探 ［D］ 唐山: 河北联合大学, 2011.
[16］王慧莲,王琦,尹春梅大黄素和小檗碱改善HepG2细胞胰岛素抵抗的机制研究 ［J］中国病理生理杂志, 2009, 25: 20442046, 2049.
[17］Weidner C, de Groot JC, Prasad A, et al.Amorfrutins are potent antidiabetic dietary natural products［J］.Proceedings of the National Academy of Sciences of the United States of America, 2012, 109(19):72577262.
[18］Mae T, Kishida H, Nishiyama T, et al A licorice ethanolic extract with peroxisome proliferatoractivated receptorγ ligandbinding activity affects diabetes in KKAy mice, abdominal obesity in dietinduced obese C57BL mice and hypertension in spontaneously hypertensive rats［J］.Journal of Nutrition, 2003, 133(11):33693377.
[19］Li C, Cao L, Zeng Q. Astragalus prevents diabetic rats from developing cardiomyopathy by downregulating angiotensin II type2 receptors' expression［J］ Journal of Huazhong University of Science and Technology, 2004, 24(4):379384
[20］Liu M, Wu K, Mao X, et al.Astragalus polysaccharide improves insulin sensitivity in KKAy mice: regulation of PKB/GLUT4 signaling in skeletal muscle［J］ Journal of Ethnopharmacology, 2010, 127(1):3237.
[21］Mao XQ, Yu F, Wang N, et al.Hypoglycemic effect of polysaccharide enriched extract of Astragalus membranaceus in diet induced insulin resistant C57BL/6J mice and its potential mechanism［J］ Phytomedicine, 2009, 16(5): 416425.
[22］Zhao M, Zhang ZF, Ding Y, et al.Astragalus polysaccharide improves palmitateinduced insulin resistance by inhibiting PTP1B and NF.kappaB in C2C12 myotubes［J］.Molecules, 2012, 17(6): 70837092.
[23］Wu Y, OuYang JP, Wu K, et al Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B［J］ Acta Pharmacologica Sinica, 2005, 26(3): 345352.
[24］Chen C, Zhang Y, Huang C Berberine inhibits PTP1B activity and mimics insulin action［J］.Biochemical and Biophysical Research Communications, 2010, 397(3): 543547.
[25］Jeong HW, Hsu KC, Lee JW, et al.Berberine suppresses proinflammatory responses through AMPK activation in macrophages［J］.American Journal of Physiology, 2009, 296(4): E955E964.
[26］Kim WS, Lee YS, Cha SH, et al.Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity［J］.American Journal of Physiology, 2009, 296(4): E812E819.
[27］Lee YS, Kim WS, Kim KH, et al.Berberine, a natural plant product, activates AMPactivated protein kinase with beneficial metabolic effects in diabetic and insulinresistant states［J］.Diabetes, 2006, 55(8): 22562264.
[28］侯君，李聃丹，王维维，等．二肽基肽酶Ⅳ抑制剂在Ⅱ型糖尿病大鼠中的降糖作用的比较［J］．华西药学杂志，2013，28(4)：360363．
[29］Mohan V, Yang W, Son HY, et al Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea［J］.Diabetes Res Clin Pract, 2009, 83(1): 106161.
[30］Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes［J］.Diabetes Care, 2006, 29(12): 26322637

相似文献/References:

[1]王倩 傅延龄 陈文强 黄小波.基于葛根芩连汤药效组分含量测定文献的中药处方用量控制研究[J].环球中医药,2017,10(08):831.[doi:10.3969/j.issn.1674-1749.2017.08.007]
　WANG Qian,FU Yanling,CHEN Wenqiang,et al.Research on dosage control of traditional Chinese medicine based on the content determination of active components alignment of Gegen Qinlian decoction[J].,2017,10(03):831.[doi:10.3969/j.issn.1674-1749.2017.08.007]

备注/Memo

备注/Memo:
基金项目：国家科技重大专项“重大新药创制”专项(2009ZX09502018)；北京中医药大学创新团队项目（2011CXTD06）；北京中医药大学在读研究生资助项目(2013JYBZZXS027)
作者单位：100102 北京中医药大学基础医学院［武志黔（硕士研究生）、郝改梅（博士研究生）、薛晓兴（硕士研究生）、何洁（硕士研究生）、王伟］，科研中心（吴晏、韩静）作者简介：武志黔（1988），2011级在读硕士研究生。研究方向：中医药防治心血管疾病的药理研究。Email：flickerstar@yeah.net通讯作者：王伟（1964），博士，出站博士后，教授，博士生导师。研究方向：中医药防治心血管疾病的药理研究。Email：wangwei@bucm.edu.cn
更新日期/Last Update: 1900-01-01